Contrave Obesity Pill Faces Manufacturing Questions In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm needs more time to respond to questions about its third-party suppliers of bupropion; CHMP’s Day 180 List of Outstanding Issues also include risk/benefit and pharmacovigilance concerns.